Many families with children being treated for acute lymphoblastic leukemia face household material hardship and/or income loss.

A treatment strategy of targeted therapy first allowed more than half of patients with newly diagnosed DLBCL to achieve a CR without chemotherapy.

Epcoritamb plus lenalidomide and rituximab improves PFS and complete response in patients with relapsed/refractory follicular lymphoma in second line compared with lenalidomide and rituximab alone.

In patients with follicular lymphoma being treated in the third-line setting or later, liso-cel therapy is associated with durable responses.

KRd significantly prolonged progression-free survival and improved the MRD negativity rate compared to VRd in newly diagnosed multiple myeloma.

Targeted immunotherapy significantly improved responses and prolonged survival in newly-diagnosed Ph+ ALL compared with chemotherapy.

Treatment with rituximab plus epcoritamab has achieved rapid and deep responses in follicular lymphoma patients with a high tumor burden.

The Isa-VRd quadruplet regimen induced sustained MRD negativity and a strong rate complete response or better in patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM).

Investigators analyzed IBD subtypes and their associated risks of radical prostatectomy complications among a cohort of patients with prostate cancer to fill a knowledge gap.

Researchers sought to determine whether adding fixed-duration venetoclax to RBAC in the first line would be effective in older patients with high-risk MCL.

A review of EMR data from younger and older women with breast cancer noted that social support was not consistently documented among patients.

In patients with advanced-stage classic Hodgkin lymphoma, a PFS benefit was seen at 3 years’ follow-up with N-AVD compared to BV-AVD.